The potential clinical value of plasma biomarkers in Alzheimer's disease

被引:29
作者
Blennow, Kaj [1 ,2 ]
Galasko, Douglas [3 ]
Perneczky, Robert [4 ,5 ,6 ,7 ,8 ]
Quevenco, Frances-Catherine [9 ]
van der Flier, Wiesje M. [10 ,11 ,12 ]
Akinwonmi, Akin [9 ]
Carboni, Margherita [9 ]
Jethwa, Alexander [13 ]
Suridjan, Ivonne [9 ]
Zetterberg, Henrik [1 ,2 ,14 ,15 ,16 ,17 ]
机构
[1] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden
[2] Sahlgrenska Univ Hosp Molndal, Clin Neurochem Lab, Molndal, Sweden
[3] Univ Calif La Jolla, Dept Neurosci, La Jolla, CA USA
[4] Univ Hosp Munich, Dept Psychiat & Psychotherapy, Munich, Germany
[5] German Ctr Neurodegenerat Dis DZNE, Munich, Germany
[6] Munich Cluster Syst Neurol SyNergy, Munich, Germany
[7] Univ Sheffield, Sheffield Inst Translat Neurosci SITraN, Sheffield, England
[8] Imperial Coll London, Sch Publ Hlth, Ageing Epidemiol AGE Res Unit, London, England
[9] Roche Diagnost Int Ltd, Forrenstr 2, CH-6343 Rotkreuz, Switzerland
[10] Amsterdam UMC, Alzheimer Ctr Amsterdam, Amsterdam Neurosci, Dept Neurol, Amsterdam, Netherlands
[11] Amsterdam UMC, Amsterdam Neurosci, Neurodegenerat, Amsterdam, Netherlands
[12] Amsterdam UMC, Dept Epidemiol & Data Sci, Amsterdam, Netherlands
[13] Roche Diagnost GmbH, Penzberg, Germany
[14] UCL, UK Dementia Res Inst, London, England
[15] UCL Inst Neurol, Dept Neurodegenerat Dis, London, England
[16] Hong Kong Ctr Neurodegenerat Dis, Hong Kong, Peoples R China
[17] Univ Wisconsin, Wisconsin Alzheimers Dis Res Ctr, Sch Med & Publ Hlth, Madison, WI USA
关键词
Alzheimer's disease; diagnosis; diagnosis pathway; diagnostic test; plasma biomarkers; triage tool; ALZHEIMERS-DISEASE; P-TAU217; ASSAYS; A-BETA-42/40; PROTEOTYPE;
D O I
10.1002/alz.13455
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
INTRODUCTION: Many people with cognitive complaints or impairment never receive an accurate diagnosis of the underlying condition, potentially impacting their access to appropriate treatment. To address this unmet need, plasma biomarker tests are being developed for use in Alzheimer's disease (AD). Plasma biomarker tests span various stages of development, including in vitro diagnostic devices (or tests) (IVDs), laboratory-developed tests (LDTs) and research use only devices (or tests) (RUOs). Understanding the differences between each test type is important for appropriate implementation into the AD diagnostic pathway and care continuum.METHODS: Authors reviewed scientific literature (PubMed, meeting abstracts and presentations, company press releases and websites) on AD plasma biomarkers.RESULTS: This article defines IVDs, LDTs, and RUOs, discusses potential clinical applications and highlights the steps necessary for their clinical implementation.DISCUSSION: Plasma biomarkers could revolutionize many areas of the AD diagnostic pathway and care continuum, but further research is needed.
引用
收藏
页码:5805 / 5816
页数:12
相关论文
共 50 条
  • [41] Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer's disease
    Siedlecki-Wullich, Dolores
    Catala-Solsona, Judit
    Fabregas, Cristina
    Hernandez, Isabel
    Clarimon, Jordi
    Lleo, Alberto
    Boada, Merce
    Saura, Carlos A.
    Rodriguez-Alvarez, Jose
    Minano-Molina, Alfredo J.
    ALZHEIMERS RESEARCH & THERAPY, 2019, 11 (1)
  • [42] Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease
    Leuzy, Antoine
    Cullen, Nicholas C.
    Mattsson-Carlgren, Niklas
    Hansson, Oskar
    CURRENT OPINION IN NEUROLOGY, 2021, 34 (02) : 266 - 274
  • [43] Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change
    Smirnov, Denis S.
    Ashton, Nicholas J.
    Blennow, Kaj
    Zetterberg, Henrik
    Simren, Joel
    Lantero-Rodriguez, Juan
    Karikari, Thomas K.
    Hiniker, Annie
    Rissman, Robert A.
    Salmon, David P.
    Galasko, Douglas
    ACTA NEUROPATHOLOGICA, 2022, 143 (04) : 487 - 503
  • [44] CSF and plasma biomarkers for early Alzheimer's disease and to monitor Aβ modulation
    Blennow, Kaj
    NEUROBIOLOGY OF AGING, 2008, 29 : S2 - S2
  • [45] Early Alzheimer's Disease Screening Approach Using Plasma Biomarkers
    Alvarez-Sanchez, Lourdes
    Pena-Bautista, Carmen
    Ferre-Gonzalez, Laura
    Cubas, Laura
    Balaguer, Angel
    Casanova-Estruch, Bonaventura
    Baquero, Miguel
    Chafer-Pericas, Consuelo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (18)
  • [46] MicroRNAs in Alzheimer's Disease: Function and Potential Applications as Diagnostic Biomarkers
    Wei, Wei
    Wang, Zhi-Yong
    Ma, Li-Na
    Zhang, Ting-Ting
    Cao, Yu
    Li, Hao
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2020, 13
  • [47] Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's Disease
    Winston, Charisse N.
    Langford, Oliver
    Levin, Natalie
    Raman, Rema
    Yarasheski, Kevin
    West, Tim
    Abdel-Latif, Sara
    Donohue, Michael
    Nakamura, Akinori
    Toba, Kenji
    Masters, Colin L.
    Doecke, James
    Sperling, Reisa A.
    Aisen, Paul S.
    Rissman, Robert A.
    JOURNAL OF ALZHEIMERS DISEASE, 2023, 92 (01) : 95 - 107
  • [48] Blood biomarkers for Alzheimer's disease with the Lumipulse automated platform: Age-effect and clinical value interpretation
    Musso, Giulia
    Gabelli, Carlo
    Puthenparampil, Marco
    Cosma, Chiara
    Cagnin, Annachiara
    Gallo, Paolo
    Soraru, Gianni
    Pegoraro, Elena
    Zaninotto, Martina
    Antonini, Angelo
    Moz, Stefania
    Zambon, Carlo Federico
    Plebani, Mario
    Corbetta, Maurizio
    Basso, Daniela
    CLINICA CHIMICA ACTA, 2025, 565
  • [49] Plasma metals as potential biomarkers in dementia: a case-control study in patients with sporadic Alzheimer's disease
    Xu, Jingshu
    Church, Stephanie J.
    Patassini, Stefano
    Begley, Paul
    Kellett, Katherine A. B.
    Vardy, Emma R. L. C.
    Unwin, Richard D.
    Hooper, Nigel M.
    Cooper, Garth J. S.
    BIOMETALS, 2018, 31 (02) : 267 - 276
  • [50] Plasma biomarkers increase diagnostic confidence in patients with Alzheimer's disease or frontotemporal lobar degeneration
    Altomare, Daniele
    Libri, Ilenia
    Alberici, Antonella
    Rivolta, Jasmine
    Padovani, Alessandro
    Ashton, Nicholas J.
    Zetterberg, Henrik
    Blennow, Kaj
    Borroni, Barbara
    ALZHEIMERS RESEARCH & THERAPY, 2024, 16 (01)